16,342 Shares in Stryker Corporation $SYK Bought by Quantbot Technologies LP

Quantbot Technologies LP bought a new stake in shares of Stryker Corporation (NYSE:SYK) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 16,342 shares of the medical technology company’s stock, valued at approximately $6,041,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new position in Stryker during the 2nd quarter valued at approximately $205,000. Arkadios Wealth Advisors raised its holdings in shares of Stryker by 17.2% in the second quarter. Arkadios Wealth Advisors now owns 4,747 shares of the medical technology company’s stock worth $1,878,000 after buying an additional 695 shares during the last quarter. HBK Sorce Advisory LLC raised its holdings in shares of Stryker by 11.0% in the second quarter. HBK Sorce Advisory LLC now owns 940 shares of the medical technology company’s stock worth $372,000 after buying an additional 93 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Stryker by 89.7% during the second quarter. Assetmark Inc. now owns 3,163 shares of the medical technology company’s stock worth $1,251,000 after buying an additional 1,496 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Performance

Shares of NYSE SYK opened at $387.34 on Friday. The company has a market capitalization of $148.23 billion, a PE ratio of 46.11, a price-to-earnings-growth ratio of 2.26 and a beta of 0.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The company’s fifty day moving average price is $363.17 and its 200 day moving average price is $369.16. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the prior year, the firm posted $4.01 earnings per share. The company’s revenue was up 11.4% compared to the same quarter last year. On average, research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio is currently 41.90%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SYK shares. UBS Group upped their target price on Stryker from $386.00 to $400.00 and gave the company a “neutral” rating in a research report on Tuesday. Barclays reissued an “overweight” rating and issued a $469.00 price objective on shares of Stryker in a report on Monday, February 2nd. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective for the company in a research note on Tuesday, January 6th. Truist Financial dropped their target price on Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research report on Thursday, December 18th. Finally, Citigroup reiterated a “market outperform” rating on shares of Stryker in a report on Friday, January 30th. Thirteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $426.47.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This represents a 9.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.